Stocks making the biggest moves premarket: Netflix, Nucor, Xenon Pharmaceuticals & more

Premarket movers were mixed: Xenon Pharmaceuticals plunged 25% after pausing new enrollment in depression trials due to neuropsychiatric side effects, while Netflix fell more than 3% following a Wells Fargo downgrade citing engagement and 2026 content concerns. Steel Dynamics and Nucor each dropped over 1.5% on weaker-than-expected Q3 guidance, whereas bitcoin's 2% rise above $78,000 lifted Robinhood by 2.5%, Coinbase by 1%, and Strategy by 3%. Macom gained 3% after BMO upgraded the shares, citing an attractive valuation following a more than 35% decline from 2026 highs.

Analysis

The steel guidance resets the near-term earnings bar for NUE and STLD, but the more important read-through is whether weakness is confined to scrap/raw-material spreads or reflects end-market destocking in non-residential construction and heavy manufacturing. NUE has greater downstream fabrication exposure, while STLD's recycling footprint creates more sensitivity to scrap-price compression; a widening HRC-scrap spread would favor NUE relative to STLD over the next 1-3 months. The structural offset is that import restrictions and domestic capacity discipline can limit downside if spot HRC stabilizes, making an outright sector short less attractive after an initial de-risking move.

NFLX's risk is not a single-quarter content issue but a potential shift from operating-leverage expectations to a lower terminal-margin framework. The stock's valuation remains unusually dependent on sustained margin expansion and ad-tier monetization; any evidence of softer engagement, ad-load pricing, or subscriber conversion in the next earnings cycle could drive multiple compression before consensus materially lowers estimates. Conversely, a strong advertising upfront season or a content slate that restores viewing share would quickly invalidate a fundamental short, so this is better expressed as a defined-risk hedge than a large directional position.

Crypto equities should not be treated as equivalent Bitcoin exposure: COIN has transaction-volume and regulatory-beta upside, HOOD can monetize broader retail risk appetite, while MSTR adds balance-sheet leverage and premium/discount-to-NAV risk. If Bitcoin's advance is driven by spot flows rather than retail turnover, COIN and HOOD may lag the underlying despite positive price action; sustained higher volatility and retail volumes are the required confirmation over coming weeks. MTSI offers the cleaner idiosyncratic long setup, but the upgrade alone is not a catalyst—orders, inventory normalization, and data-center optical demand need confirmation at the next report. XENE's enrollment pause introduces an unquantifiable program-duration and label-risk issue; the asymmetry remains negative until management discloses incidence, severity, reversibility, and regulatory feedback.

Key Decisions for Investors

• Initiate a 1-3 month relative-value position: long NUE / short STLD in equal dollar amounts only if HRC-scrap spreads stabilize or widen over the next two weeks. Target 8-12% relative return; exit if scrap inflation narrows the spread materially or NUE cuts downstream/fabrication outlook.
• Buy NFLX 3-6 month put spreads rather than shorting stock outright, sized as a hedge against media/consumer-discretionary exposure. The thesis requires downward FY2027-28 margin revisions; close if next earnings show engagement stabilization plus ad-tier monetization sufficient to support consensus operating-margin expectations.
• Prefer COIN over MSTR for tactical crypto upside only after confirmation from rising exchange volumes and sustained Bitcoin strength for several sessions. Use a 10-15% trailing risk limit: MSTR's leverage and NAV-premium volatility make it the weaker risk-adjusted expression if Bitcoin merely grinds higher without retail participation.
• Place MTSI on a long watch list for entry ahead of its next earnings report, contingent on management reaffirming data-center and industrial order momentum. A position is justified only if forward revenue expectations stop declining; otherwise the apparent valuation support can remain a value trap.
• Avoid adding XENE exposure until adverse-event disclosure quantifies severity and the enrollment restart timeline. A restart alone is insufficient; the key falsifier is evidence that protocol changes eliminate recurrence without impairing efficacy or delaying pivotal-study completion.